Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype
Status:
Unknown status
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The project is a double-blind, randomized, placebo controlled clinical trial comparing 3
groups of schizophrenic subjects, who have no less than moderate degree of negative symptoms
and carry the homozygous risk genotype (TT) of NRG1-P3, each group having 30 individuals,
treated by add-on with escitalopram 10-20 mg/day, duloxetine 30-60 mg/day, and placebo. The
treatment duration is 8 week. The investigators will evaluate the Positive and Negative
Symptom Scale (PANSS) at baseline, Day 14, Day 28, Day 42, and Day 56. The primary outcome of
interest will be the differences of averaged reduction of negative symptom scores among 3
groups and an average decrease of 2 or more in the negative symptoms will be indicated as
improvement.